|
MELBOURNE, Australia, Feb. 4, 2026 /PRNewswire/ -- It is exciting to share that FlexRule® has been recognized as Niche Player in the 2026 Gartner® Magic Quadrant™ for Decision Intelligence Platforms.
"We are thrilled to be included in the first-ever Gartner® Magic Quadrant™ for Decision Intelligence Platforms. We believe this recognition supports our Decision-Centric Approach® and confirms that it fills a critical gap where traditional data-driven approaches fall short. Our approach enables organizations to move from BI to DI using a practical decision-centric methodology, supported by our Open Decision Intelligence Platform." said Arash Aghlara, CEO of FlexRule.
FlexRule's Decision-Centric Approach®: Enables organizations to consistently make optimized, customer-centric and situation-aware business decisions.
"Our methodology makes decisions the first-class citizens of organizations so that they leverage our platform to explicitly model decisions using an open standard (Decision Model and Notation with Conformance Level 3, DMN) and therefore, these decision models become the foundation for decision automation and augmentation across various use cases and a wide range of industries such as Banking, Financial Services, Insurance and Government.
Together, the Decision-Centric Approach® and the Open Decision Intelligence Platform accelerate organizations' transition from traditional data-driven (BI) practices to a decision-centric enterprise." said Arash Aghlara, CEO of FlexRule.
The Gartner® Magic Quadrant™ evaluates vendors based on their Ability to Execute and Completeness of Vision. We are honored to be included among the recognized vendors in this important report.
Learn more about the Magic Quadrant.
Source: Gartner Report, Magic Quadrant for Decision Intelligence Platforms, By David Pidsley, Carlie Idoine, etc, January 2026.
Gartner and Magic Quadrant are a trademark of Gartner, Inc. and/or its affiliates.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About FlexRule®:
FlexRule® is an innovative Decision Intelligence company that provides technology (Open Decision Intelligence Platform) and methodology (Decision-Centric Approach®), empowering enterprises to automate, augment, and govern their decisions at scale.
We accelerate organizations' transition from traditional data-driven models to decision-centric organizations. The Decision-Centric Approach® enables enterprises to make optimized, customer-centric, and situation-aware business decisions by treating decisions as first-class citizens and governing them as enterprise assets.
Media Contact:
Goli Tajadod
FlexRule Pty Ltd
Goli.Tajadod@FlexRule.com
+1 (323) 99 960 39
MELBOURNE, Australia, Feb. 4, 2026 /PRNewswire/ -- It is exciting to share that FlexRule® has been recognized as Niche Player in the 2026 Gartner® Magic Quadrant™ for Decision Intelligence Platforms.
"We are thrilled to be included in the first-ever Gartner® Magic Quadrant™ for Decision Intelligence Platforms. We believe this recognition supports our Decision-Centric Approach® and confirms that it fills a critical gap where traditional data-driven approaches fall short. Our approach enables organizations to move from BI to DI using a practical decision-centric methodology, supported by our Open Decision Intelligence Platform." said Arash Aghlara, CEO of FlexRule.
FlexRule's Decision-Centric Approach®: Enables organizations to consistently make optimized, customer-centric and situation-aware business decisions.
"Our methodology makes decisions the first-class citizens of organizations so that they leverage our platform to explicitly model decisions using an open standard (Decision Model and Notation with Conformance Level 3, DMN) and therefore, these decision models become the foundation for decision automation and augmentation across various use cases and a wide range of industries such as Banking, Financial Services, Insurance and Government.
Together, the Decision-Centric Approach® and the Open Decision Intelligence Platform accelerate organizations' transition from traditional data-driven (BI) practices to a decision-centric enterprise." said Arash Aghlara, CEO of FlexRule.
The Gartner® Magic Quadrant™ evaluates vendors based on their Ability to Execute and Completeness of Vision. We are honored to be included among the recognized vendors in this important report.
Learn more about the Magic Quadrant.
Source: Gartner Report, Magic Quadrant for Decision Intelligence Platforms, By David Pidsley, Carlie Idoine, etc, January 2026.
Gartner and Magic Quadrant are a trademark of Gartner, Inc. and/or its affiliates.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About FlexRule®:
FlexRule® is an innovative Decision Intelligence company that provides technology (Open Decision Intelligence Platform) and methodology (Decision-Centric Approach®), empowering enterprises to automate, augment, and govern their decisions at scale.
We accelerate organizations' transition from traditional data-driven models to decision-centric organizations. The Decision-Centric Approach® enables enterprises to make optimized, customer-centric, and situation-aware business decisions by treating decisions as first-class citizens and governing them as enterprise assets.
Media Contact:
Goli Tajadod
FlexRule Pty Ltd
Goli.Tajadod@FlexRule.com
+1 (323) 99 960 39
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
FlexRule® has been recognized as Niche Player in the 2026 Gartner® Magic Quadrant™ for Decision Intelligence Platforms
HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.
Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.
To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).
Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.
Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.
The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.
Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.
This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.
These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.
Media Contact:
Chi Zhang
media@westlake.edu.cn
+86-15659837873
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform
